Displaying drugs 7401 - 7425 of 8178 in total
Talacotuzumab
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly …
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of …
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
Matched Description: … people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of …
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Matched Description: … IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. …
Ciliary neurotrophic factor
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
Investigational
Matched Description: … [L46762] It is under investigation for the treatment of retinitis pigmentosa and age-related macular …
Reparixin
Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.
Investigational
Matched Description: … Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic …
Inolimomab
Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.
Investigational
Matched Description: … far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of …
Nurulimab
Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in Subjects With Unresectable/metastatic Melanoma).
Investigational
Matched Description: … Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
ATG003
ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
Investigational
Matched Description: … ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical …
ABT-560
ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
Investigational
Matched Description: … receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of …
Riferminogene pecaplasmid
Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
Investigational
Matched Description: … fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of …
Lirilumab
Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.
Investigational
Matched Description: … Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic …
Spebrutinib
Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.
Investigational
Matched Description: … Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell …
Preladenant
Preladenant has been used in trials studying the treatment of Brain Diseases, Parkinson Disease, Movement Disorders, Antipsychotic Agents, and Parkinsonian Disorders, among others.
Investigational
Matched Description: … Preladenant has been used in trials studying the treatment of Brain Diseases, Parkinson Disease, Movement …
JNJ-39393406
JNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia, Smoking Cessation, Cognition Disorders, and Alzheimer's Disease.
Investigational
Matched Description: … JNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia …
Alanyl glutamine
Alanyl Glutamine is under investigation in clinical trial NCT00338221 (Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition).
Investigational
Matched Description: … Alanyl Glutamine is under investigation in clinical trial NCT00338221 (Clinical Trial of Alanyl-Glutamine …
Vadastuximab talirine
Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
Investigational
Matched Description: … Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic …
Galunisertib
Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.
Investigational
Matched Description: … Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid …
AZD-1981
AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.
Investigational
Matched Description: … AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic …
RRx-001
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
Matched Description: … RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma …
Lorvotuzumab mertansine
Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Investigational
Matched Description: … Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer …
Displaying drugs 7401 - 7425 of 8178 in total